Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours

BACKGROUND: Olaparib, an oral PARP inhibitor, has shown antitumour activity as monotherapy in patients with germline BRCA1/2 (gBRCA)-mutated breast and ovarian cancer. This study evaluated olaparib capsules in combination with liposomal doxorubicin (PLD) in patients with advanced solid tumours (NCT0...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Del Conte, G, Sessa, C, von Moos, R, Viganò, L, Digena, T, Locatelli, A, Gallerani, E, Fasolo, A, Tessari, A, Cathomas, R, Gianni, L
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2014
Témata:
Clinical Study
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4134498/
https://ncbi.nlm.nih.gov/pubmed/25025963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.345
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky